HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
- PMID: 20388636
- DOI: 10.1093/jac/dkq099
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
Abstract
Background: Our aim was to study the in vivo viral genetic pathways for resistance to raltegravir, in antiretroviral-experienced patients with virological failure (VF) on raltegravir-containing regimens.
Methods: We set up a prospective study including antiretroviral-experienced patients receiving raltegravir-based regimens. Integrase (IN) genotypic resistance analysis was performed at baseline. IN was also sequenced at follow-up points in the case of VF, i.e. plasma HIV-1 RNA>400 copies/mL at month 3 and/or >50 copies/mL at month 6. For phenotyping, the IN region was recombined with an IN-deleted HXB2-based HIV-1 backbone. A titrated amount of IN recombinant viruses was used for antiviral testing against raltegravir and elvitegravir.
Results: Among 51 patients, 11 (21.6%) had VF. Four different patterns of IN mutations were observed: (i) emergence of Q148H/R with secondary mutations (n=5 patients); (ii) emergence of N155H, then replaced by a pattern including Y143C/H/R (n=3); (iii) selection of S230N (n=1); and (iv) no evidence of selection of IN mutations (n=2). The median raltegravir and elvitegravir fold changes (FCs) were 244 (154-647) and 793 (339-892), respectively, for the Q148H/R pattern, while the median raltegravir and elvitegravir FCs were 21 (6-52) and 3 (2-3), respectively, with Y143C/H/R. The median plasma raltegravir Cmin was lower in patients with selection of the N155H mutation followed by Y143C/H/R compared with patients with Q148H/R and with patients without emerging mutations or without VF.
Conclusions: Diverse genetic profiles can be associated with VF on raltegravir-containing regimens, including the dynamics of replacement of mutational profiles. Pharmacokinetic parameters could be involved in this genetic evolution.
Similar articles
-
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z. Retrovirology. 2018. PMID: 29304821 Free PMC article.
-
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28. Antimicrob Agents Chemother. 2008. PMID: 18227187 Free PMC article.
-
Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24. J Antimicrob Chemother. 2010. PMID: 20736234
-
Characterization and structural analysis of HIV-1 integrase conservation.AIDS Rev. 2009 Jan-Mar;11(1):17-29. AIDS Rev. 2009. PMID: 19290031 Review.
-
[Resistance to integrase inhibitors].Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:40-6. doi: 10.1016/s0213-005x(08)76572-8. Enferm Infecc Microbiol Clin. 2008. PMID: 19572425 Review. Spanish.
Cited by
-
In vitro evolution of an HIV integrase binding protein from a library of C-terminal domain γS-crystallin variants.Bioorg Med Chem Lett. 2012 Sep 1;22(17):5584-9. doi: 10.1016/j.bmcl.2012.07.008. Epub 2012 Jul 10. Bioorg Med Chem Lett. 2012. PMID: 22858140 Free PMC article.
-
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes.Viruses. 2014 Oct 20;6(10):3855-72. doi: 10.3390/v6103855. Viruses. 2014. PMID: 25333465 Free PMC article. Review.
-
Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.Antimicrob Agents Chemother. 2013 Sep;57(9):4105-13. doi: 10.1128/AAC.00204-13. Epub 2013 Jun 3. Antimicrob Agents Chemother. 2013. PMID: 23733474 Free PMC article.
-
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.BMC Infect Dis. 2012 Dec 21;12:368. doi: 10.1186/1471-2334-12-368. BMC Infect Dis. 2012. PMID: 23259737 Free PMC article.
-
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.J Med Chem. 2011 Apr 14;54(7):2282-92. doi: 10.1021/jm1014378. Epub 2011 Mar 7. J Med Chem. 2011. PMID: 21381765 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases